Nurix Therapeutics Past Earnings Performance
Past criteria checks 0/6
Nurix Therapeutics's earnings have been declining at an average annual rate of -36.7%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 44.3% per year.
Key information
-36.7%
Earnings growth rate
19.8%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 44.3% |
Return on equity | -85.8% |
Net Margin | -178.9% |
Last Earnings Update | 29 Feb 2024 |
Recent past performance updates
Recent updates
Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies
Apr 15Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues
Apr 14Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet
Feb 20Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now
Jan 16Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation
Dec 29Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues
Oct 14Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher
Oct 13Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation
Sep 30Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts
Apr 18We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully
Apr 15We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate
Nov 28Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M
Oct 06Nurix Therapeutics GAAP EPS of -$1.01 misses by $0.02, revenue of $11.43M beats by $0.93M
Jul 07FDA approves expansion of Nurix Therapeutics' phase 1 trial of NX-1607 into the U.S.
Jun 30We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully
Jun 21We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth
Mar 07Nurix: Advancing Targeted Protein Modulation Therapies
Nov 21Companies Like Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Invest In Growth
Nov 21We're Not Worried About Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn
Jul 24Nurix Therapeutics appoints new operations chief
Jun 21Nurix Therapeutics adds Clay Siegall to its board of directors
Jun 01Here's Why We're Not At All Concerned With Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation
Apr 15Revenue & Expenses BreakdownBeta
How Nurix Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
29 Feb 24 | 81 | -145 | 45 | 0 |
30 Nov 23 | 77 | -144 | 43 | 0 |
31 Aug 23 | 69 | -149 | 41 | 0 |
31 May 23 | 61 | -157 | 41 | 0 |
28 Feb 23 | 42 | -179 | 39 | 0 |
30 Nov 22 | 39 | -180 | 38 | 0 |
31 Aug 22 | 39 | -171 | 37 | 0 |
31 May 22 | 39 | -154 | 36 | 0 |
28 Feb 22 | 34 | -135 | 34 | 0 |
30 Nov 21 | 30 | -117 | 31 | 0 |
31 Aug 21 | 29 | -99 | 29 | 0 |
31 May 21 | 23 | -89 | 25 | 0 |
28 Feb 21 | 20 | -63 | 20 | 0 |
30 Nov 20 | 18 | -43 | 16 | 0 |
31 Aug 20 | 13 | -37 | 13 | 0 |
31 May 20 | 19 | -21 | 11 | 0 |
29 Feb 20 | 25 | -24 | 9 | 0 |
30 Nov 19 | 31 | -22 | 8 | 0 |
30 Nov 18 | 37 | -9 | 7 | 0 |
Quality Earnings: NRIX is currently unprofitable.
Growing Profit Margin: NRIX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NRIX is unprofitable, and losses have increased over the past 5 years at a rate of 36.7% per year.
Accelerating Growth: Unable to compare NRIX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NRIX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: NRIX has a negative Return on Equity (-85.77%), as it is currently unprofitable.